Heron Therapeutics (HRTX) 18.14 $HRTX
Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors
BusinessWire - Wed Jun 22, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced the appointment of Christian Waage to Heron's Board of Directors.
HRTX: 18.14 (+0.25)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 18.14 (+0.25), TXMD: 8.85 (+0.27), RMTI: 7.44 (+0.20), SNY: 41.19 (+0.90)
Heron Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 3:51PM CDT
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $33.4 million in its first quarter.
HRTX: 18.14 (+0.25)
Heron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress
BusinessWire - Thu May 05, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs, today reported first quarter 2016 financial results and highlighted recent corporate progress.
HRTX: 18.14 (+0.25)
This Was the Best Performing Healthcare ETF Last Week
Brian Feroldi, The Motley Fool - Motley Fool - Sat Apr 23, 2:17PM CDT
Source: TBIT ON PIXABAY. It was a terrific week to have money invested in the healthcare sector, as the majority of the largest exchange-traded funds that focus on the space smashed the returns of the S&P 500 . Several of these ETFs gained...
HRTX: 18.14 (+0.25), PJP: 63.38 (+0.99)
These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.15 (-0.01), SGYP: 3.80 (unch), HRTX: 18.14 (+0.25), RPRX: 1.70 (+0.07)
Is Heron Therapeutics' Stock Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 19, 8:24AM CDT
Image source: Pixabay. What : Shares of Heron Therapeutics gained over 18% in pre-market trading today on heavy volume after the company announced that there are no remaining substantive deficiencies in the New Drug Application for Sustol, and...
HRTX: 18.14 (+0.25)
Heron Therapeutics Provides Update on FDA Review of SUSTOL(R) NDA
BusinessWire - Mon Apr 18, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL(R) (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.
HRTX: 18.14 (+0.25)
Heron Therapeutics Provides Update on SUSTOL(R) NDA
BusinessWire - Thu Mar 03, 5:30AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), announced today that the U.S. Food and Drug Administration (FDA) has informed the Company that it anticipates concluding its review of the New Drug Application (NDA) of SUSTOL(R) (granisetron) Injection, extended release, by early April 2016. The Company is working closely with the FDA to facilitate the completion of its review.
HRTX: 18.14 (+0.25)
How Risky Is Heron Therapeutics Stock?
Cory Renauer, The Motley Fool - Motley Fool - Sun Feb 21, 10:02AM CST
Last spring, Sustol from Heron Therapeutics proved itself capable of reducing chemotherapy-induced nausea and vomiting in a group with limited options. Since the announcement, the stock has been on a epic roller-coaster ride. Now on its ...
HRTX: 18.14 (+0.25)
Heron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress
BusinessWire - Fri Feb 19, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs, today reported fourth quarter and full year 2015 financial results and highlighted recent corporate progress.
HRTX: 18.14 (+0.25)
Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 34.59 (+0.12), ALKS: 43.75 (+0.71), ZYNE: 7.77 (+0.49), XNPT: 7.03 (+0.02), OMER: 10.98 (+0.12), INSY: 13.07 (+0.29), NBIX: 44.59 (+1.86), TNXP: 2.15 (+0.08), HRTX: 18.14 (+0.25), ABBV: 61.31 (+0.92), ARNA: 1.91 (+0.06)
Why Heron Therapeutics' Stock Sank Today
George Budwell, The Motley Fool - Motley Fool - Mon Feb 08, 11:45AM CST
What : Shares of the biotech company Heron Therapeutics sank by as much as 15.8% today on greater-than-normal volume for the stock. The good news is that this latest downturn wasn't triggered by a negative catalyst; rather, the stock appears to be...
HRTX: 18.14 (+0.25)
Heron Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET (10:25 a.m. PT) in New York, NY.
HRTX: 18.14 (+0.25)
Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.39 (+0.06), COLL: 13.70 (+0.41), LLY: 73.94 (+0.87), AGN: 233.51 (+4.96), JNJ: 117.38 (+0.92), INSY: 13.07 (+0.29), EGLT: 5.61 (+0.54), ACAD: 33.50 (unch), CLCD: 6.72 (-0.06), HRTX: 18.14 (+0.25), AZN: 29.29 (+0.59), ABBV: 61.31 (+0.92), PTIE: 2.07 (+0.02)
Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development
M2 - Fri Jan 29, 3:48AM CST
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) revealed on Thursday the addition of Kimberly J. Manhard as executive vice president of its drug development.
HRTX: 18.14 (+0.25)
Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development
BusinessWire - Thu Jan 28, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of Kimberly J. Manhard as Executive Vice President of Drug Development. Ms. Manhard joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.
HRTX: 18.14 (+0.25)
Heron (HRTX) Down, Sustol Review Period Extended by FDA
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 2:05PM CST
Heron Therapeutics, Inc. (HRTX) announced that that the FDA has not yet completed its review process for the marketing application for Sustol.
HRTX: 18.14 (+0.25), GILD: 83.37 (+0.92), GSK: 42.56 (+0.80), ANIK: 51.10 (+0.83)
7 Stocks to Buy in January
Steve Symington, Evan Niu, CFA, Daniel Miller, Matthew DiLallo, Andrés Cardenal, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Wed Jan 13, 9:32PM CST
After the broader market's painful pullback so early this year, skittish investors might be tempted to run for the hills. But for those willing to resist the urge and maintain their composure, this also means opportunity. To capitalize on that...
NFLX: 91.66 (+1.65), HRTX: 18.14 (+0.25), GILD: 83.37 (+0.92), MRK: 57.68 (+0.64), CMG: 408.89 (+15.90), EOG: 84.50 (+0.90), WMT: 72.10 (+0.35), ABBV: 61.31 (+0.92), RGR: 62.83 (+0.97), SWHC: 25.33 (-0.15)
Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors
BusinessWire - Wed Jun 22, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced the appointment of Christian Waage to Heron's Board of Directors.
HRTX: 18.14 (+0.25)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 18.14 (+0.25), TXMD: 8.85 (+0.27), RMTI: 7.44 (+0.20), SNY: 41.19 (+0.90)
Heron Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 3:51PM CDT
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $33.4 million in its first quarter.
HRTX: 18.14 (+0.25)
Heron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress
BusinessWire - Thu May 05, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs, today reported first quarter 2016 financial results and highlighted recent corporate progress.
HRTX: 18.14 (+0.25)
This Was the Best Performing Healthcare ETF Last Week
Brian Feroldi, The Motley Fool - Motley Fool - Sat Apr 23, 2:17PM CDT
Source: TBIT ON PIXABAY. It was a terrific week to have money invested in the healthcare sector, as the majority of the largest exchange-traded funds that focus on the space smashed the returns of the S&P 500 . Several of these ETFs gained...
HRTX: 18.14 (+0.25), PJP: 63.38 (+0.99)
These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.15 (-0.01), SGYP: 3.80 (unch), HRTX: 18.14 (+0.25), RPRX: 1.70 (+0.07)
Is Heron Therapeutics' Stock Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 19, 8:24AM CDT
Image source: Pixabay. What : Shares of Heron Therapeutics gained over 18% in pre-market trading today on heavy volume after the company announced that there are no remaining substantive deficiencies in the New Drug Application for Sustol, and...
HRTX: 18.14 (+0.25)
Heron Therapeutics Provides Update on FDA Review of SUSTOL(R) NDA
BusinessWire - Mon Apr 18, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL(R) (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.
HRTX: 18.14 (+0.25)
Heron Therapeutics Provides Update on SUSTOL(R) NDA
BusinessWire - Thu Mar 03, 5:30AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), announced today that the U.S. Food and Drug Administration (FDA) has informed the Company that it anticipates concluding its review of the New Drug Application (NDA) of SUSTOL(R) (granisetron) Injection, extended release, by early April 2016. The Company is working closely with the FDA to facilitate the completion of its review.
HRTX: 18.14 (+0.25)
How Risky Is Heron Therapeutics Stock?
Cory Renauer, The Motley Fool - Motley Fool - Sun Feb 21, 10:02AM CST
Last spring, Sustol from Heron Therapeutics proved itself capable of reducing chemotherapy-induced nausea and vomiting in a group with limited options. Since the announcement, the stock has been on a epic roller-coaster ride. Now on its ...
HRTX: 18.14 (+0.25)
Heron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress
BusinessWire - Fri Feb 19, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs, today reported fourth quarter and full year 2015 financial results and highlighted recent corporate progress.
HRTX: 18.14 (+0.25)
Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 34.59 (+0.12), ALKS: 43.75 (+0.71), ZYNE: 7.77 (+0.49), XNPT: 7.03 (+0.02), OMER: 10.98 (+0.12), INSY: 13.07 (+0.29), NBIX: 44.59 (+1.86), TNXP: 2.15 (+0.08), HRTX: 18.14 (+0.25), ABBV: 61.31 (+0.92), ARNA: 1.91 (+0.06)
Why Heron Therapeutics' Stock Sank Today
George Budwell, The Motley Fool - Motley Fool - Mon Feb 08, 11:45AM CST
What : Shares of the biotech company Heron Therapeutics sank by as much as 15.8% today on greater-than-normal volume for the stock. The good news is that this latest downturn wasn't triggered by a negative catalyst; rather, the stock appears to be...
HRTX: 18.14 (+0.25)
Heron Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET (10:25 a.m. PT) in New York, NY.
HRTX: 18.14 (+0.25)
Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.39 (+0.06), COLL: 13.70 (+0.41), LLY: 73.94 (+0.87), AGN: 233.51 (+4.96), JNJ: 117.38 (+0.92), INSY: 13.07 (+0.29), EGLT: 5.61 (+0.54), ACAD: 33.50 (unch), CLCD: 6.72 (-0.06), HRTX: 18.14 (+0.25), AZN: 29.29 (+0.59), ABBV: 61.31 (+0.92), PTIE: 2.07 (+0.02)
Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development
M2 - Fri Jan 29, 3:48AM CST
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) revealed on Thursday the addition of Kimberly J. Manhard as executive vice president of its drug development.
HRTX: 18.14 (+0.25)
Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development
BusinessWire - Thu Jan 28, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of Kimberly J. Manhard as Executive Vice President of Drug Development. Ms. Manhard joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.
HRTX: 18.14 (+0.25)
Heron (HRTX) Down, Sustol Review Period Extended by FDA
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 2:05PM CST
Heron Therapeutics, Inc. (HRTX) announced that that the FDA has not yet completed its review process for the marketing application for Sustol.
HRTX: 18.14 (+0.25), GILD: 83.37 (+0.92), GSK: 42.56 (+0.80), ANIK: 51.10 (+0.83)
7 Stocks to Buy in January
Steve Symington, Evan Niu, CFA, Daniel Miller, Matthew DiLallo, Andrés Cardenal, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Wed Jan 13, 9:32PM CST
After the broader market's painful pullback so early this year, skittish investors might be tempted to run for the hills. But for those willing to resist the urge and maintain their composure, this also means opportunity. To capitalize on that...
NFLX: 91.66 (+1.65), HRTX: 18.14 (+0.25), GILD: 83.37 (+0.92), MRK: 57.68 (+0.64), CMG: 408.89 (+15.90), EOG: 84.50 (+0.90), WMT: 72.10 (+0.35), ABBV: 61.31 (+0.92), RGR: 62.83 (+0.97), SWHC: 25.33 (-0.15)
